Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (64)

I-01Leon Aarons

Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children

Wednesday 10:15-11:45

I-02

Population Pharmacokinetic Analysis and Effects of Raltegravir In HIV positive and Healthy Individuals

Wednesday 10:15-11:45

I-03

Development of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic Fibrosis

Wednesday 10:15-11:45

I-04Hesham Al-Sallami

A semi-mechanistic model for estimating fat free mass in children

Wednesday 10:15-11:45

I-05Claire Ambery

Modelling impact of dropout mechanisms in Chronic Obstructive Pulmonary Disease (COPD)

Wednesday 10:15-11:45

I-06

Predictive Model for Identification of Responders/Non Responders in Metastatic Breast Cancer Patients Treated with Docetaxel

Wednesday 10:15-11:45

I-07Anders Kristoffersson

Optimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects.

Wednesday 10:15-11:45

I-08

Trial Sample Size Estimation and Study Design Assessment using Monte Carlo Sampling

Wednesday 10:15-11:45

I-09Jacqueline Anderson

Comparative pharmacokinetics of dimethoate poisoning in the minipig and human

Wednesday 10:15-11:45

I-10Christian Bartels

Population PK Model for Pooled Data of Different Oral Diclofenac Formulations

Wednesday 10:15-11:45

I-11Paul Baverel

A novel covariate search method intended for PKPD models with nonparametric parameter distributions

Wednesday 10:15-11:45

I-12Caroline Bazzoli

New features for population design evaluation and optimisation with R functions: PFIM Interface 3.1 and PFIM 3.2

Wednesday 10:15-11:45

I-13Benoît Beck

From the Experimental Model Settings to the Physical System for Interpretable Decision Making

Wednesday 10:15-11:45

I-14Francesco Bellanti

Relevance of QT-RR correlations in the assessment of QTc-interval prolongation in clinical trial simulations

Wednesday 10:15-11:45

I-15Brendan Bender

A semi-mechanistic population Pharmacokinetic-Pharmacodynamic (PKPD) model of thrombocytopenia characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

Wednesday 10:15-11:45

I-16Julie Bertrand

Extensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients

Wednesday 10:15-11:45

I-17Julie Bertrand

Multiple SNP analysis with HyperLasso in Pharmacogenetic Studies using Nonlinear Mixed Effects Models

Wednesday 10:15-11:45

I-18Bruno Bieth

Using a Systems Biology Approach to Explore Clinical Diversity and Investigate Mechanism of Drug Action: Example of the RAAS System in Hypertension

Wednesday 10:15-11:45

I-19Roberto Bizzotto

Drug Effects on Sleep Data from a 28-Day Clinical Study in Insomniac Patients: Covariate Analysis Using a Multinomial Mixed-Effect Markov-Chain Model

Wednesday 10:15-11:45

I-20Marcus Björnsson

Performance of non-linear mixed effects models with and without taking informative dropout into account

Wednesday 10:15-11:45

I-21Michael Block

Mechanistic PBPK/PD modeling for prediction of study outcome of cancer therapies: Translating in-vitro information into valid in-vivo predictions

Wednesday 10:15-11:45

I-22Irina Bondareva

Sequential Interacting Multiple Model (IMM) Bayesian Analysis of Carbamazepine and Valproate Repeated Therapeutic Drug Monitoring (TDM) Data from Epileptic Patients

Wednesday 10:15-11:45

I-23Guillaume Bonnefois

A nonlinear mixed effect model to study albumin-mediated drug transport into endothelial cells in vitro.

Wednesday 10:15-11:45

I-24Stephan Borghorst

Age Dependent Volume of Distribution of Pegylated Asparaginase (OncasparTM) in children and adults

Wednesday 10:15-11:45

I-25

A Negative feedback model for a mechanism based description of longitudinal observations: application for bone turnover biomarkers.

Wednesday 10:15-11:45

I-26Marion Bouillon-Pichault

Modeling Pain score in clinical trials using a joint survival-longitudinal mixed model with a Beta distribution in presence of missing values not occurring at random.

Wednesday 10:15-11:45

I-27Marion Bouillon-Pichault

Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4

Wednesday 10:15-11:45

I-28Christine Brandquist

PK/PD Modeling of the Effect of Intravenous Doses of Anzemet® (dolasetron mesylate) and Its Metabolite (hydrodolasetron) on the QT Interval in Healthy Subjects

Wednesday 10:15-11:45

I-29Karl Brendel

A comparison of MONOLIX, NONMEM 6 and NONMEM 7 based on a simulated PK example

Wednesday 10:15-11:45

I-30Margreke Brill

Cefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery.

Wednesday 10:15-11:45

I-31Anne Brochot

Specifying Models with Time Dependent Pharmacokinetic Parameters in NONMEM

Wednesday 10:15-11:45

I-32Jacob Brogren

Separate vs. simultaneous analysis of co-primary endpoints in Alzheimer’s disease clinical trials

Wednesday 10:15-11:45

I-33Vincent Buchheit

Efficient quality review for modeling input dataset

Wednesday 10:15-11:45

I-34Núria Buil Bruna

The feasibility of model-based exposure calculations in preclinical toxicology

Wednesday 10:15-11:45

I-35Vicente G. Casabo

Bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

Wednesday 10:15-11:45

I-36Massimo Cella

Implementation of Pharmacokinetic Bridging for Drug Combinations in Children

Wednesday 10:15-11:45

I-37Anne Chain

Can First-Time-In-Human Trials Replace Thorough QT Studies?

Wednesday 10:15-11:45

I-38Pascal Chanu

A dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH)

Wednesday 10:15-11:45

I-39

Pharmacokinetics of doripenem in cerebrospinal fluid

Wednesday 10:15-11:45

I-41Marylore Chenel

Developing an In Vitro – In Vivo Correlation Model Using a Population Approach in NONMEM

Wednesday 10:15-11:45

I-42Marylore Chenel

BSA-adjusted dose? An old method to fight old bias

Wednesday 10:15-11:45

I-43S. Y. Amy Cheung

Structural identifiability of parallel pharmacokinetic experiments as constrained systems

Wednesday 10:15-11:45

I-44Jason Chittenden

Evaluation of the Lindstrom-Bates FOCE Algorithm with Simulated Pharmacokinetic Datasets

Wednesday 10:15-11:45

I-45Steve Choy

Application of an integrated glucose-insulin model to investigate the effects of glibenclamide and its active metabolites on postprandial glucose and insulin concentrations in healthy volunteers

Wednesday 10:15-11:45

I-46Christine Xu

Population Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV

Wednesday 10:15-11:45

I-47Jae Yong Chung

Modelling of Atorvastatin Pharmacokinetics in relation to SLCO1B1 genotype and Simulations for Bioequivalence Study

Wednesday 10:15-11:45

I-48Karina Blei

Evaluation of a PBPK Model for Preterm Neonates by Predicting Paracetamol Pharmacokinetics

Wednesday 10:15-11:45

I-49Adriaan Cleton

Population Pharmacokinetics of a Monoclonal Antibody Tanezumab in Chronic Pelvic Pain Conditions

Wednesday 10:15-11:45

I-50Emmanuelle Comets

SAEMIX, an R version of the SAEM algorithm

Wednesday 10:15-11:45

I-51Emmanuelle Comets

Prediction discrepancies (pd) for evaluation of models with data under limit of quantification

Wednesday 10:15-11:45

I-52Emmanuelle Comets

A comparison of bootstrap approaches for estimating standard errors of parameters in linear mixed effects models

Wednesday 10:15-11:45

I-53

Utilising prior literature population models to inform clinical practice – a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdose

Wednesday 10:15-11:45

I-54Alexander Danis

Set-valued methods for estimation of parameters in population models

Wednesday 10:15-11:45

I-55

Maturation of GFR in preterm and term neonates reflected by clearance of different antibiotics

Wednesday 10:15-11:45

I-56Elizabeth de Lange

Mechanism-based PK-PD model of remoxipride with rat-to-human extrapolation: characterizing remoxipride target site PK and systems homeostatic feedback

Wednesday 10:15-11:45

I-57Willem de Winter

Dynamics of a Two-Receptor Binding Model: How Affinities and Capacities Translate into Long- and Short-Term Behaviour and Physiological Corollaries

Wednesday 10:15-11:45

I-58Maud Delattre

Pharmacokinetics and stochastic differential equations : model and methodology.

Wednesday 10:15-11:45

I-59Ivan Demin

Longitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug development

Wednesday 10:15-11:45

I-60Paolo Denti

Population PK of Isoniazid in South African Adults.

Wednesday 10:15-11:45

I-61Vincenzo Luca Di Iorio

Application of Stochastic Differential Equations to Disease Progression in a Neuropathic Pain Model in Rats

Wednesday 10:15-11:45

I-62

Pharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites

Wednesday 10:15-11:45

I-63Jeroen Diepstraten

Pharmacodynamics of nadroparin using anti-Xa levels in morbidly obese patients upon subcutaneous administration of 5700 IU

Wednesday 10:15-11:45

I-64Aris Dokoumetzidis

Numerical solution of nonlinear fractional compartmental systems

Wednesday 10:15-11:45

I-65Aris Dokoumetzidis

Multiple dosing for linear fractional pharmacokinetic systems

Wednesday 10:15-11:45